Episode 28: Top 10 Highlights of the 2023 NANETS Symposium

EPISODE 28: TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM

Download a Transcript of this Episode >>

ABOUT THIS EPISODE

In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist, Dr. Guillaume (Will) Pegna, recaps the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and discusses why they matter to the NET patient community.

MEET DR. GUILLAUME PEGNA

Dr. Pegna is a medical oncologist who specializes in the care of adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors including pheochromocytomas, paragangliomas and adrenocortical carcinomas as well as other gastrointestinal cancers.

Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys.

TOP 10 HIGHLIGHTS OF THE 2023 NANETS SYMPOSIUM REFERENCES

Honorable Mentions:

C-46 - "P eptide Receptor Radionuclide Therapy Improves Survival in Patients Who Progress After Resection of Gastroenteropancreatic Neuroendocrine Tumors"

Luis C. Borbon et al

C-51 - "A Prospective Phase II Single-Arm Trial on Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE Followed by Surgery for Pancreatic Neuroendocrine Tumors (NeoLuPaNET)"

Stefano Partelli et al

Top 10:

10. C-39 - "Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Neoplasms: A NET Center of Excellence Experience"

Dr. Grewal at University of Iowa Holden Cancer Center & Lindsay Hunter, MD, Huntsman Cancer Institute

9. C-25 - "Pilot Study of Pembrolizumab and Peptide Receptor Radionuclide Therapy for Patients with Metastatic Well-Differentiated Neuroendocrine Tumors"

Preliminary results of a prospective clinical trial by Nicholas Fidelman, MD, et al

8. C-1 - "Clinical impact of unsuccessful subcutaneous administration of octreotide LAR instead of intramuscular administration in patients living with metastatic neuroendocrine tumors"

Retrospective study by Dr. Krishnan and Dr. Loree out of Vancouver BC

7. O-5 - "Chromogranin A as Surveillance biomarker in Patients with cARcinoids (CASPAR)"

Study by Dr. Halfdanarson, et al

6. C-55 -"Association of Long-Term PPI Use With Low-Risk Gastric Neuroendocrine Tumor"

Oral presentation by Taymeyah Al-Toubah, MPH, and Jonathan Strosberg, MD

5. C-47 - "Surgical Cytoreduction vs Systemic therapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS): NCDB Analysis"

Abstract from Dr. Mohamed et al, Case Western Reserve University, Cleveland Ohio

4.a. C-5 - "A Phase 2 Clinical Trial of Cabozantinib in Patients with Unresectable and Progressive Metastatic Pheochromocytoma or Paraganglioma: The NATALIE Trial"

Dr. Camilo Jimenez from MD Anderson Cancer Center

4.b. C-22 - "Phase 2 Trial of Lu-177-DOTATATE in Metastatic or Inoperable Pheochromocytoma/Paraganglioma: Interim Analysis Results"

NIH Trial led by Dr. Frank Lin

3.a. O-9 - "Prevalence of Clonal Hematopoiesis (CH) in Neuroendocrine Tumor (NET) Patients Prior to Lutetium 177 Dotatate (Lu177): A Prospective Study"

Mohamad Bassam Sonbol et al

3.b. C-32 - "Myelodysplasia and Leukemia Instances After PRRT: Experience From a Tertiary Institution"

Nikolaos Trikalinos, MD et al

2.a. C-11 - "Transformation of Low-Intermediate Grade Neuroendocrine Tumors into High Grade Morphology"

Dr. McGlothlin and Dr. Halfdanarson at Mayo Clinic

2.b. C-48 - "Predictors of Low-to-High Grade Progression in Pancreatic Neuroendocrine Tumors"

Poster by Stephanie Wang and Dr. Emily Bergsland at UCSF

1.a. C-14 - "Cabozantinib as Salvage Therapy for Well Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs)"

Rylie Schnell and Dr. Halfdanarson, Mayo Clinic Comprehensive Cancer Center

1.b. C-3 - "Real-World Evidence of Lenvatinib Use for Treatment of Metastatic Neuroendocrine Neoplasms"

Joao Paulo Solar Vasconcelos et al

ABOUT NANETS

The North American Neuroendocrine Tumor Society (NANETS) provides NET medical educational programming designed exclusively for medical professionals. While our Podcast only features 10 presentations from the NANETS October 4-6, 2023 Symposium, there are many more noteworthy abstracts found (or listed) here:

NANETS Abstracts Library
2023 NANETS Abstracts Booklet

While NANETS does not provide direct patient education, patients may help further NET education of medical professionals by sharing the organization's educational meetings and NET guidelines with their providers.

RESOURCES

LISTEN

Previous NANETS Highlights Podcast

CLINICAL TRIAL INFORMATION

NET Retreat Trial Information

DISCLAIMER

LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment.